MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate
MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate
Wednesday, MacroGenics Inc (NASDAQ:MGNX) provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) for metastatic castration-resistant prostate cancer (mCRPC).
週三，MacroGenics Inc（納斯達克股票代碼：MGNX）提供了TAMARACK針對轉移性去勢耐藥性前列腺癌（mcRPC）的沃布拉米他布多卡嗪（vobra duo，前身爲 MGC018）的2期研究的最新情況。
As previously disclosed, safety data from the company's ongoing TAMARACK Phase 2 study was submitted in early February to the American Society of Clinical Oncology for presentation.
正如先前披露的那樣，該公司正在進行的TAMARACK 2期研究的安全性數據已於2月初提交給美國臨床腫瘤學會進行介紹。
The abstract containing this early interim data, based on a January 4, 2024, data cutoff, was not accepted.
包含這些基於2024年1月4日數據截止日期的早期中期數據的摘要未被接受。
"While the TAMARACK data will not be presented at the ASCO Annual Meeting, we intend to maintain our previously disclosed plan to share further TAMARACK interim data, including updated safety and preliminary efficacy, by the end of May," said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer.
總裁兼首席執行官斯科特·科尼格醫學博士、博士表示：“儘管TAMARACK的數據不會在ASCO年會上公佈，但我們打算維持先前披露的計劃，即在5月底之前分享更多的TAMARACK中期數據，包括最新的安全性和初步療效。”
At the data cutoff (January 4, 2024), 182 patients with mCRPC enrolled on TAMARACK, of which 177 received vobra duo.
在數據截止時（2024年1月4日），182名mcRPC患者註冊了TAMARACK，其中177名接受了vobra duo。
Thirty (16.5%) had visceral disease at baseline, 109 (59.9%) had RECIST-evaluable disease, and 98 (53.8%) received prior docetaxel.
三十人（16.5％）在基線時患有內臟疾病，109人（59.9％）患有可重試評估的疾病，98人（53.8％）以前接受過多西他賽治療。
At this early data cut, patients have received a median of 3 (range 1 to 7) cycles of vobra duo; treatment is ongoing in 156 (85.7%).
在這次早期的數據削減中，患者接受的vobra duo週期中位數爲3（範圍爲1至7）；156個（85.7％）仍在進行治療。
Preliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability.
來自TAMARACK的初步安全數據表明，減少vobra duo的劑量和頻率可以提高其安全性和耐受性。
The company plans to provide updated interim data, including safety and preliminary efficacy, by May 31.
該公司計劃在5月31日之前提供最新的中期數據，包括安全性和初步療效。
JMP Securities writes that Vobra-duo's safety profile has dramatically enhanced with its new quarterly dosing regimen. This change has resulted in a notable decrease in treatment interruptions and discontinuations, potentially enhancing its effectiveness.
JMP Securities寫道，Vobra-Duo的新季度給藥方案顯著提高了其安全性。這種變化顯著減少了治療中斷和中止的次數，有可能提高其有效性。
The analyst maintains the Market Outperform rating and a price target of $22.
分析師維持市場跑贏大盤的評級和22美元的目標股價。
JMP Securities analysts say they are impressed by the enhanced safety profile, particularly with fewer treatment interruptions and dose reductions, which could result in increased exposure and improved effectiveness compared to previous data.
JMP Securities的分析師表示，安全性的提高給他們留下了深刻的印象，尤其是減少了治療中斷次數和減少了劑量，與先前的數據相比，這可能會增加暴露量並提高有效性。
Additionally, JMP finds it encouraging that most patients received a median of three cycles of vobra-duo, with 86% continuing treatment.
此外，JMP感到鼓舞的是，大多數患者接受的vobra-duo的平均週期爲三個週期，86％的患者繼續接受治療。
Price Action: MGNX shares are up 33.6% at $18.26 on the last check Thursday.
價格走勢：在週四的最後一次支票中，MGNX股價上漲33.6％，至18.26美元。
Photo via Shutterstock
照片來自 Shutterstock
譯文內容由第三人軟體翻譯。